



24 December 2020

**OMEGA DIAGNOSTICS GROUP PLC**  
**("Omega" or the "Company" or the "Group")**

**Mologic CE Mark Rapid Antigen Test**

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, welcomes the news that Mologic Ltd ("Mologic") has received CE Mark for its professional-use COVID-19 Rapid Antigen Test.

In June this year, the Company signed a material transfer agreement ("MTA") with Mologic providing access to raw materials and know-how to manufacture their lateral flow antigen test. The test will provide health professionals an accurate detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.

As announced at the Interim results in November 2020, Omega has now established its technology transfer team and look forward to updating shareholders in the New Year on how the technology transfer and CE Mark is going, so the Company can sell the Rapid Test under Omega's VISITECT<sup>®</sup> brand.

**Colin King, CEO of Omega Diagnostics, said:** *"We welcome the news that Mologic has received CE Mark for its Rapid Antigen Test, and are excited about completing the technology transfer and CE Marking in the New Year."*

**Contacts:**

**Omega Diagnostics Group PLC**

Bill Rhodes, Interim Non-Executive Chairman  
Colin King, Chief Executive  
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030  
[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

**finnCap Ltd**

Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus  
Lianne Cawthorne

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)  
Mob: 07980 541 893  
Mob: 07584 391 303